|
1
|
Breast cancer, . World Health
Organization. 2021.[updated 26 March 2021]. Available from:.
https://www.who.int/news-room/fact-sheets/detail/breast-cancer
|
|
2
|
Kennecke H, Yerushalmi R, Woods R, Cheang
MCU, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic
behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al-Mahmood S, Sapiezynski J, Garbuzenko OB
and Minko T: Metastatic and triple-negative breast cancer:
Challenges and treatment options. Drug Deliv Transl Res.
8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mayer IA, Abramson VG, Lehmann BD and
Pietenpol JA: New strategies for triple-negative breast
cancer-deciphering the heterogeneity. Clin Cancer Res. 20:782–790.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu J, Wu KJ, Jia QJ and Ding XF: Roles of
miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ
Sci B. 21:673–689. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang H, Xie J, Zhang M, Zhao Z, Wan Y and
Yao Y: miRNA-21 promotes proliferation and invasion of
triple-negative breast cancer cells through targeting PTEN. Am J
Transl Res. 9:953–961. 2017.PubMed/NCBI
|
|
8
|
Chen H, Pan H, Qian Y, Zhou W and Liu X:
MiR-25-3p promotes the proliferation of triple negative breast
cancer by targeting BTG2. Mol Cancer. 17:42018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X,
Zhou C and Jiao D: Identification of microRNA-93 as a functional
dysregulated miRNA in triple-negative breast cancer. Tumour Biol.
36:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y
and Li L: MicroRNA-455-3p promotes invasion and migration in triple
negative breast cancer by targeting tumor suppressor EI24.
Oncotarget. 8:19455–19466. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amini S, Abak A, Estiar MA, Montazeri V,
Abhari A and Sakhinia E: Expression analysis of MicroRNA-222 in
breast cancer. Clin Lab. 64:491–496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Falkenberg N, Anastasov N, Rappl K,
Braselmann H, Auer G, Walch A, Huber M, Höfig I, Schmitt M, Höfler
H, et al: MiR-221/-222 differentiate prognostic groups in advanced
breast cancers and influence cell invasion. Br J Cancer.
109:2714–2723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Phannasil P, Thuwajit C, Warnnissorn M,
Wallace JC, MacDonald MJ and Jitrapakdee S: Pyruvate carboxylase is
up-regulated in breast cancer and essential to support growth and
invasion of MDA-MB-231 cells. PLoS One. 10:e01298482015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McGeary SE, Lin KS, Shi CY, Pham TM,
Bisaria N, Kelley GM and Bartel DP: The biochemical basis of
microRNA targeting efficacy. Science. 366:eaav17412019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Y and Wang X: miRDB: An online
database for prediction of functional microRNA targets. Nucleic
Acids Res. 48(D1): D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, Da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akekawatchai C, Roytrakul S, Kittisenachai
S, Isarankura-Na-Ayudhya P and Jitrapakdee S: Protein profiles
associated with anoikis resistance of metastatic MDA-MB-231 breast
cancer cells. Asian Pac J Cancer Prev. 17:581–590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McGuire A, Brown JA and Kerin MJ:
Metastatic breast cancer: The potential of miRNA for diagnosis and
treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song Q, An Q, Niu B, Lu X, Zhang N and Cao
X: Role of miR-221/222 in tumor development and the underlying
mechanism. J Oncol. 2019:72520132019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H
and Zhou X: MicroRNA-222 regulates cell invasion by targeting
matrix metalloproteinase 1 (MMP1) and manganese superoxide
dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
Cancer Genomics Proteomics. 6:131–139. 2009.PubMed/NCBI
|
|
24
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu K, Liang X, Shen K, Sun L, Cui D, Zhao
Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance
in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell
Res. 318:2168–2177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo F, Zhou J, Wang S, Sun Z, Han Q and
Bai C: microRNA-222 promotes colorectal cancer cell migration and
invasion by targeting MST3. FEBS Open Bio. 9:901–913. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao H, Cong X, Zhou J and Guan M:
MicroRNA-222 influences migration and invasion through MIA3 in
colorectal cancer. Cancer Cell Int. 17:782017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li S, Li Q, Lü J, Zhao Q, Li D, Shen L,
Wang Z, Liu J, Xie D, Cho WC, et al: Targeted inhibition of
miR-221/222 promotes cell sensitivity to cisplatin in
triple-negative breast cancer MDA-MB-231 cells. Front Genet.
10:12782020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Said MN, Muawia S, Helal A, Fawzy A, Allam
RM and Shafik NF: Regulation of CDK inhibitor p27 by microRNA 222
in breast cancer patients. Exp Mol Pathol. 123:1047182021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang
M, Xu Y and Tang J: Exosome-mediated miR-222 transferring: An
insight into NF-κB-mediated breast cancer metastasis. Exp Cell Res.
369:129–138. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Malagobadan S and Nagoor NH: Evaluation of
MicroRNAs regulating anoikis pathways and its therapeutic
potential. Biomed Res Int. 2015:7168162015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mak CS, Yung MM, Hui LM, Leung LL, Liang
R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, et al: MicroRNA-141
enhances anoikis resistance in metastatic progression of ovarian
cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer.
16:112017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fornari F, Gramantieri L, Ferracin M,
Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM,
Bolondi L and Negrini M: MiR-221 controls CDKN1C/p57 and CDKN1B/p27
expression in human hepatocellular carcinoma. Oncogene.
27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Y, Cui H and Wang X: Downregulation
of EIF5A2 by miR-221-3p inhibits cell proliferation, promotes cell
cycle arrest and apoptosis in medulloblastoma cells. Biosci
Biotechnol Biochem. 83:400–408. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang L, Song F, Sun H, Zhang L and Huang
C: IRX5 promotes NF-κB signalling to increase proliferation,
migration and invasion via OPN in tongue squamous cell carcinoma. J
Cell Mol Med. 22:3899–3910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie X, Huang Y, Chen L and Wang J: miR-221
regulates proliferation and apoptosis of ovarian cancer cells by
targeting BMF. Oncol Lett. 16:6697–6704. 2018.PubMed/NCBI
|
|
37
|
Cochrane DR, Cittelly DM, Howe EN,
Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D and Richer JK:
MicroRNAs link estrogen receptor alpha status and Dicer levels in
breast cancer. Horm Cancer. 1:306–319. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu Q, Ren X, Zhang Y, Fu X, Li Y, Peng Y,
Xiao Q, Li T, Ouyang C, Hu Y, et al: MiR-221-3p targets ARF4 and
inhibits the proliferation and migration of epithelial ovarian
cancer cells. Biochem Biophys Res Commun. 497:1162–1170. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fuso P, Di Salvatore M, Santonocito C,
Guarino D, Autilio C, Mulè A, Arciuolo D, Rinninella A, Mignone F,
Ramundo M, et al: Let-7a-5p, miR-100-5p, miR-101-3p, and
miR-199a-3p hyperexpression as potential predictive biomarkers in
early breast cancer patients. J Pers Med. 11:8162021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Poloznikov AA, Nikulin SV, Raigorodskaya
MP, Fomicheva KA, Zakharova GS, Makarova YA and Alekseev BY:
Changes in the metastatic properties of MDA-MB-231 cells after
IGFBP6 gene knockdown is associated with increased expression of
miRNA genes controlling INSR, IGF1R, and CCND1 genes. Bull Exp Biol
Med. 166:641–645. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yi D, Wang R, Shi X, Xu L, Yilihamu Y and
Sang J: METTL14 promotes the migration and invasion of breast
cancer cells by modulating N6-methyladenosine and has-miR-146a-5p
expression. Oncol Rep. 43:1375–1386. 2020.PubMed/NCBI
|
|
42
|
Poodineh J, Sirati-Sabet M, Rajabibazl M
and Mohammadi-Yeganeh S: MiR-130a-3p blocks Wnt signaling cascade
in the triple-negative breast cancer by targeting the key players
at multiple points. Heliyon. 6:e054342020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun S, Ma J, Xie P, Wu Z and Tian X:
Hypoxia-responsive miR-141-3p is involved in the progression of
breast cancer via mediating the HMGB1/HIF-1α signaling pathway. J
Gene Med. 22:e32302020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xiao Y, Humphries B, Yang C and Wang Z:
MiR-205 dysregulations in breast cancer: The complexity and
opportunities. Noncoding RNA. 5:532019.PubMed/NCBI
|
